Olanzapine "long-acting" therapy in schizophrenic patients: clinical dimensions and plasma levels

被引：0
|
作者：
Paletta, S. [1 ]
Di Pace, C. [1 ]
Maffini, M. [1 ]
Reggiori, A. [1 ]
Mauri, M. C. [1 ]
Altamura, A. C. [1 ]
机构：
[1] Fdn IRCCS Osped Maggiore, Psychiat Clin, Milan, Italy
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70884-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.051
引用
收藏
页码：S552 / S553
页数：2
相关论文
共 50 条
  • [1] OLANZAPINE "LONG-ACTING" IN MAINTENANCE THERAPY OF SCHIZOPHRENIA: A STUDY WITH PLASMA LEVELS
    Altamura, A. C.
    Rovera, Chiara
    Di Pace, C.
    Paletta, S.
    De Gaspari, I. F.
    MAuri, M. C.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S299 - S300
  • [2] "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels
    Mauri, Massimo C.
    Maffini, Michele
    Di Pace, Chiara
    Reggiori, Alessandra
    Paletta, Silvia
    Moliterno, Donatella
    Rovera, Chiara
    Altamura, Carlo A.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2015, 19 (02) : 99 - 105
  • [3] Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
    Heres, Stephan
    Kraemer, Susanne
    Bergstrom, Richard F.
    Detke, Holland C.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) : 299 - 312
  • [4] Clinical improvement with long-acting risperidone in patients previously receiving oral olanzapine
    Jones, R
    Lasser, R
    Bossie, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S303 - S304
  • [5] Risperidone long-acting formulation in treatment-resistant schizophrenic patients the predictive value of plasma levels in relation to clinical response and safety
    Cerveri, G.
    Volonteri, L. S.
    De Gasperi, I.
    Papini, B.
    Papa, P.
    Mauri, M. C.
    Mencacci, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S524 - S524
  • [6] Paliperidone palmitate long-acting injection in schizophrenic patients
    Suarez Gisbert, E.
    EUROPEAN PSYCHIATRY, 2020, 63 : S540 - S540
  • [7] LONG-ACTING PHENOTHIAZINES IN PREVENTION OF RELAPSE OF SCHIZOPHRENIC PATIENTS
    DENHAM, J
    ADAMSON, L
    CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL, 1973, 18 (03): : 235 - 237
  • [8] Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients
    Woltering, Eugene A.
    Salvo, Vergilio A.
    O'Dorisio, Thomas M.
    Lyons, John, III
    Li, Gang
    Zhou, Ying
    Seward, Jacky R.
    Go, Vay Liang W.
    Vinik, Arthur I.
    Mamikunian, Paris
    Mamikunian, Gregg
    PANCREAS, 2008, 37 (01) : 94 - 100
  • [9] COST-EFFECTIVENESS OF LONG-ACTING OLANZAPINE VERSUS LONG-ACTING RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA IN SPAIN
    Dilla, T.
    O'Donohoe, P.
    Moeller, J.
    Alvarez, M.
    Sacristan, J.
    San, L.
    Happich, M.
    Tockhorn, A.
    VALUE IN HEALTH, 2011, 14 (07) : A292 - A292
  • [10] Long-acting olanzapine: clinical practice analysis in a psychiatric hospital
    Leven, Cyril
    Harry, Maud
    Langree, Bastien
    Marie, Nicolas
    Burgot, Gwenola
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 229 - 229
12345